28162-88-1

Upstream product

• 6515-58-8 3-bromomethylbenzoic acid 
• 17356-08-0 thiourea 
• 31719-77-4 3-chloromethylbenzoic acid 
• 1382034-00-5 methyl 3-(acetylsulfanylmethyl)benzoate 
• 873464-04-1 thioacetic acid S-(3-carboxybenzyl) ester 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 99-04-7 m-Toluic acid 
• 383401-01-2 3-[(4-methoxy-phenyl)-diphenyl-methylsulfanylmethyl]-benzoic acid 

Downstream Products

• 95902-29-7 methyl 3-(mercaptomethyl)benzoate 
• 121-91-5 isophthalic acid 
• 99-04-7 m-Toluic acid 
• 383401-01-2 3-[(4-methoxy-phenyl)-diphenyl-methylsulfanylmethyl]-benzoic acid 
• 536710-83-5 3-tert-butyldisulfanylmethyl-benzoic acid 
• 1354722-18-1 tert-butyl 3-(3-(4-chloro-2-(1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-ylcarbamoyl)phenylcarbamoyl)benzylthio)propanoate 
• 1354721-65-5 3-((3-((4-chloro-2-((1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)carbamoyl)phenyl)carbamoyl)benzyl)thio)propanoic acid 
• 1354722-10-3 tert-butyl 3-((3-((2-((1-(3,4-dimethylphenyl)-1H-pyrazol-3-yl)carbamoyl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzyl)thio)propanoate 
• 1354721-64-4 3-((3-((2-((1-(3,4-dimethylphenyl)-1H-pyrazol-3-yl)carbamoyl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 
• 1354722-05-6 tert-butyl 3-(3-(4-chloro-2-(1-(3,4-dimethylphenyl)-1H-pyrazol-3-yl-carbamoyl)phenylcarbamoyl)benzylthio)propanoate 
• 1354722-00-1 tert-butyl 3-((3-(chlorocarbonyl)benzyl)thio)propanoate 

Relevant academic research and scientific papers

Fluorescent-labeled excision type nucleotide, synthetic method and application of fluorescent-labeled excision type nucleotide in DNA sequencing

The invention relates to a fluorescent-labeled excision type nucleotide. The fluorescent-labeled excision type nucleotide is characterized by comprising a structure as shown in the general formula (I), wherein in the general formula (I), Fluorescent repre

Compounds and methods for inhibiting phosphate transport

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac

COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac

Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds

A series of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors have been synthesized with either a 3-(mercaptomethyl)benzoic acid or 2-(2-mercaptoethyl)benzoic acid scaffold. Potent inhibitors were identified from each of the two scaffolds with IC50 values in the single-digit nanomolar range, including 2-(3-carboxybenzyloxy)-5-(mercaptomethyl)benzoic acid 27c and 3-(2-mercaptoethyl)biphenyl-2,3'-dicarboxylicacid 35c. Compound 35c was found to be metabolically stable and selective over a number of targets related to glutamate-mediated neurotransmission. Furthermore, compound 35c was found to be orally available in rats and exhibited efficacy in an animal model of neuropathic pain following oral administration.

ANTIBACTERIAL AGENTS

The present invention relates to antibacterial agents that are useful for sterilization, sanitation, antisepsis, and disinfection.

NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS

Compounds of formula (I) and their pharmaceutically acceptable salts are provided as well as processes for the manufacture of such compounds. The compounds are useful in the treatment or prevention of inflammatory and allergic diseases.

Parallel synthesis of glycomimetic libraries: targeting a C-type lectin.

We have developed methods for the parallel synthesis of two libraries of non-carbohydrate-based analogues of mannose on a solid support. The natural product shikimic acid was used as a key building block. The ability of the compounds to block the binding of the C-type lectin MBP-A to a mannosylated surface was assessed in a high-throughput assay. Ten library members with inhibitory activities equivalent to that of alpha-methyl mannopyranoside were identified. [reaction: see text]

Naaladase inhibitors for treating retinal disorders and glaucoma

The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.

S-4-Methoxytrityl mercapto acids: Synthesis and application

4-Methoxytrityl (Mmt)-mercapto acids were obtained either by the reaction of mercapto acids with Mmt-chloride or by the reaction of halo acids with Mmt-thiol. The derivatives obtained were used in the solid-phase synthesis of small libraries of mercaptoacylamino acids and mercaptoacyl peptides. The removal of the Mmt-group was performed by treatment with trifluoroacetic acid (TFA) in dichloromethane (DCM) using triethylsilane (TES) as scavenger.